Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption

Yi Lu, Zhong Cai, Guozhi Xiao, Evan T. Keller, Atsushi Mizokami, Zhi Yao, G. David Roodman, Jian Zhang

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Prostate cancer preferentially metastasizes to bone, resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlying osteoclastic activities. We and others have previously shown that blocking receptor activator of nuclear factor-κB ligand (RANKL) partially blocks tumor establishment and progression in bone in murine models. However, levels of RANKL in the cell lines used in these studies were very low, suggesting that soluble factors other than RANKL may mediate the cancer-induced osteoclast activity. To identify these factors, a human cytokine antibody array was used to measure cytokine expression in conditioned medium collected from primary prostate epithelial cells (PrEC), prostate cancer LNCaP and its derivative C4-2B, and PC3 cells. All prostate cancer cells produced high amounts of monocyte chemotactic protein-1 (MCP-1) compared with PrEC cells. Furthermore, levels of interleukin (IL)-6, IL-8, GROα, ENA-78, and CXCL-16 were higher in PC3 than LNCaP. These results were confirmed by ELISA. Finally, human bone marrow mononuclear cells (HBMC) were cultured with PC3 conditioned medium. Although both recombinant human MCP-1 and IL-8 directly stimulated HBMC differentiation into osteoclast-like cells, IL-8, but not MCP-1, induced bone resorption on dentin slices with 21 days of culture in the absence of RANKL. However, the conditioned medium-induced bone resorption was inhibited by MCP-1 neutralizing antibody and was further synergistically inhibited with IL-8 antibody, indicating that MCP-1, in addition to IL-8, mediates tumor-induced osteoclastogenesis and bone resorption. MCP-1 may promote preosteoclast cell fusion, forming multinucleated tartrate-resistant acid phosphatase-positive osteoclast-like cells. This study may provide novel therapeutic targets for treatment of prostate cancer skeletal metastasis.

Original languageEnglish (US)
Pages (from-to)3646-3653
Number of pages8
JournalCancer Research
Volume67
Issue number8
DOIs
StatePublished - Apr 15 2007
Externally publishedYes

Fingerprint

Bone Neoplasms
Chemokine CCL2
Bone Resorption
Prostatic Neoplasms
Interleukin-8
Osteoclasts
Conditioned Culture Medium
Bone Marrow Cells
Prostate
Neoplasms
Epithelial Cells
Cytokines
Neoplasm Metastasis
Bone and Bones
Cell Fusion
Antibodies
Dentin
Cytoplasmic and Nuclear Receptors
Neutralizing Antibodies
Osteogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lu, Y., Cai, Z., Xiao, G., Keller, E. T., Mizokami, A., Yao, Z., ... Zhang, J. (2007). Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Research, 67(8), 3646-3653. https://doi.org/10.1158/0008-5472.CAN-06-1210

Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. / Lu, Yi; Cai, Zhong; Xiao, Guozhi; Keller, Evan T.; Mizokami, Atsushi; Yao, Zhi; Roodman, G. David; Zhang, Jian.

In: Cancer Research, Vol. 67, No. 8, 15.04.2007, p. 3646-3653.

Research output: Contribution to journalArticle

Lu, Y, Cai, Z, Xiao, G, Keller, ET, Mizokami, A, Yao, Z, Roodman, GD & Zhang, J 2007, 'Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption', Cancer Research, vol. 67, no. 8, pp. 3646-3653. https://doi.org/10.1158/0008-5472.CAN-06-1210
Lu, Yi ; Cai, Zhong ; Xiao, Guozhi ; Keller, Evan T. ; Mizokami, Atsushi ; Yao, Zhi ; Roodman, G. David ; Zhang, Jian. / Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. In: Cancer Research. 2007 ; Vol. 67, No. 8. pp. 3646-3653.
@article{5fddf6f7647244b58a58b9901e7bb0c5,
title = "Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption",
abstract = "Prostate cancer preferentially metastasizes to bone, resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlying osteoclastic activities. We and others have previously shown that blocking receptor activator of nuclear factor-κB ligand (RANKL) partially blocks tumor establishment and progression in bone in murine models. However, levels of RANKL in the cell lines used in these studies were very low, suggesting that soluble factors other than RANKL may mediate the cancer-induced osteoclast activity. To identify these factors, a human cytokine antibody array was used to measure cytokine expression in conditioned medium collected from primary prostate epithelial cells (PrEC), prostate cancer LNCaP and its derivative C4-2B, and PC3 cells. All prostate cancer cells produced high amounts of monocyte chemotactic protein-1 (MCP-1) compared with PrEC cells. Furthermore, levels of interleukin (IL)-6, IL-8, GROα, ENA-78, and CXCL-16 were higher in PC3 than LNCaP. These results were confirmed by ELISA. Finally, human bone marrow mononuclear cells (HBMC) were cultured with PC3 conditioned medium. Although both recombinant human MCP-1 and IL-8 directly stimulated HBMC differentiation into osteoclast-like cells, IL-8, but not MCP-1, induced bone resorption on dentin slices with 21 days of culture in the absence of RANKL. However, the conditioned medium-induced bone resorption was inhibited by MCP-1 neutralizing antibody and was further synergistically inhibited with IL-8 antibody, indicating that MCP-1, in addition to IL-8, mediates tumor-induced osteoclastogenesis and bone resorption. MCP-1 may promote preosteoclast cell fusion, forming multinucleated tartrate-resistant acid phosphatase-positive osteoclast-like cells. This study may provide novel therapeutic targets for treatment of prostate cancer skeletal metastasis.",
author = "Yi Lu and Zhong Cai and Guozhi Xiao and Keller, {Evan T.} and Atsushi Mizokami and Zhi Yao and Roodman, {G. David} and Jian Zhang",
year = "2007",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-06-1210",
language = "English (US)",
volume = "67",
pages = "3646--3653",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption

AU - Lu, Yi

AU - Cai, Zhong

AU - Xiao, Guozhi

AU - Keller, Evan T.

AU - Mizokami, Atsushi

AU - Yao, Zhi

AU - Roodman, G. David

AU - Zhang, Jian

PY - 2007/4/15

Y1 - 2007/4/15

N2 - Prostate cancer preferentially metastasizes to bone, resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlying osteoclastic activities. We and others have previously shown that blocking receptor activator of nuclear factor-κB ligand (RANKL) partially blocks tumor establishment and progression in bone in murine models. However, levels of RANKL in the cell lines used in these studies were very low, suggesting that soluble factors other than RANKL may mediate the cancer-induced osteoclast activity. To identify these factors, a human cytokine antibody array was used to measure cytokine expression in conditioned medium collected from primary prostate epithelial cells (PrEC), prostate cancer LNCaP and its derivative C4-2B, and PC3 cells. All prostate cancer cells produced high amounts of monocyte chemotactic protein-1 (MCP-1) compared with PrEC cells. Furthermore, levels of interleukin (IL)-6, IL-8, GROα, ENA-78, and CXCL-16 were higher in PC3 than LNCaP. These results were confirmed by ELISA. Finally, human bone marrow mononuclear cells (HBMC) were cultured with PC3 conditioned medium. Although both recombinant human MCP-1 and IL-8 directly stimulated HBMC differentiation into osteoclast-like cells, IL-8, but not MCP-1, induced bone resorption on dentin slices with 21 days of culture in the absence of RANKL. However, the conditioned medium-induced bone resorption was inhibited by MCP-1 neutralizing antibody and was further synergistically inhibited with IL-8 antibody, indicating that MCP-1, in addition to IL-8, mediates tumor-induced osteoclastogenesis and bone resorption. MCP-1 may promote preosteoclast cell fusion, forming multinucleated tartrate-resistant acid phosphatase-positive osteoclast-like cells. This study may provide novel therapeutic targets for treatment of prostate cancer skeletal metastasis.

AB - Prostate cancer preferentially metastasizes to bone, resulting in high mortality. Strategies to inhibit prostate cancer metastasis include targeting both tumor-induced osteoblastic lesions and underlying osteoclastic activities. We and others have previously shown that blocking receptor activator of nuclear factor-κB ligand (RANKL) partially blocks tumor establishment and progression in bone in murine models. However, levels of RANKL in the cell lines used in these studies were very low, suggesting that soluble factors other than RANKL may mediate the cancer-induced osteoclast activity. To identify these factors, a human cytokine antibody array was used to measure cytokine expression in conditioned medium collected from primary prostate epithelial cells (PrEC), prostate cancer LNCaP and its derivative C4-2B, and PC3 cells. All prostate cancer cells produced high amounts of monocyte chemotactic protein-1 (MCP-1) compared with PrEC cells. Furthermore, levels of interleukin (IL)-6, IL-8, GROα, ENA-78, and CXCL-16 were higher in PC3 than LNCaP. These results were confirmed by ELISA. Finally, human bone marrow mononuclear cells (HBMC) were cultured with PC3 conditioned medium. Although both recombinant human MCP-1 and IL-8 directly stimulated HBMC differentiation into osteoclast-like cells, IL-8, but not MCP-1, induced bone resorption on dentin slices with 21 days of culture in the absence of RANKL. However, the conditioned medium-induced bone resorption was inhibited by MCP-1 neutralizing antibody and was further synergistically inhibited with IL-8 antibody, indicating that MCP-1, in addition to IL-8, mediates tumor-induced osteoclastogenesis and bone resorption. MCP-1 may promote preosteoclast cell fusion, forming multinucleated tartrate-resistant acid phosphatase-positive osteoclast-like cells. This study may provide novel therapeutic targets for treatment of prostate cancer skeletal metastasis.

UR - http://www.scopus.com/inward/record.url?scp=34248545487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248545487&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-1210

DO - 10.1158/0008-5472.CAN-06-1210

M3 - Article

C2 - 17440076

AN - SCOPUS:34248545487

VL - 67

SP - 3646

EP - 3653

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -